Publications

• Placebo Effects in the Treatment of Depression-Implications for the Psychedelic Renaissance.Ansari M, Elliott SI, Holmes SE, Sanacora G. Neurol Clin. 2026 Feb; 2025 Sep 24. PMID: 41232997.
• Longitudinal associations of electroconvulsive therapy with all-cause mortality and suicide deaths in severe unipolar or bipolar depression: a systematic review and meta-analysis.Rhee TG, Shim S, Nasir M, McIntyre RS, Kaster TS, Wilkinson ST. BMJ Ment Health. 2025 Dec 17; 2025 Dec 17. PMID: 41407487.
• The relationship between marital status and risk for suicidal thoughts, plans, and attempts: Evidence for a growing association.Cranney S, Wilkinson ST. J Affect Disord. 2025 Dec 15; 2025 Jul 17. PMID: 40683538.
• Evaluating a New Addition to the Treatment Toolbox for Major Depressive Disorder.Sanacora G, Katz RB. Am J Psychiatry. 2025 Dec 1; 2025 Dec 1. PMID: 41320819.
• Measuring Dopamine Transporter Availability and Synaptic Density in Parkinson's Disease: A Dual-Tracer Positron Emission Tomography Imaging Study.Sadabad FE, Volpi T, Honhar P, Tinaz S, Dias M, Toyonaga T, Naganawa M, Gallezot JD, Yang Y, Ibrahim W, Pittman B, Cayir S, Radhakrishnan R, Angarita GA, Holmes SE, Comley R, Carson RE, Finnema SJ, Matuskey D. Mov Disord. 2025 Dec; 2025 Oct 3. PMID: 41040062.
• Safety and Efficacy of the NMDA-2b-Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder.McIntyre RS, Sanacora G, Walling DP, Cohen EA, Malhotra S, Rosenbrock H, Schmitz M, Scholz A, Süssmuth SD, De Crescenzo F. Clin Pharmacol Ther. 2025 Nov; 2025 Aug 14. PMID: 40810366.
• Optimized reference region and the effect on test-retest reliability and detection of Parkinson's disease with [(11)C]UCB-J.Khattar N, Matuskey D, Gallezot JD, Naganawa M, Holmes SE, Sadabad FE, Mayeli M, Esterlis I, van Dyck CH, Mecca AP, D'Souza DC, Nabulsi NB, Finnema SJ, Huang Y, Carson RE, Toyonaga T. bioRxiv. 2025 Oct 15; 2025 Oct 15. PMID: 41279573.
• Real-World Outcomes of Brexanolone to Treat Postpartum Depression.Barrett M, Hettema J, Youngman C, Wilkinson ST, Dalthorp R. Womens Health Rep (New Rochelle). 2025; 2025 Oct 6. PMID: 41142477.
• Transdiagnostic connectome-based predictive modeling of many behavioral phenotypes reveals brain network mediators of clinical-cognitive relationships.Simon AJ, Samardzija A, Iannone S, Rodriguez FP, Mehta S, Arora J, Tokoglu F, Qiu M, Tang KY, Flanagan AQ, Katz R, Sanacora G, Woods SW, Srihari VH, Shen X, Scheinost D, Constable RT. bioRxiv. 2025 Oct 2; 2025 Oct 2. PMID: 41256713.
• Synaptic Pathology in Traumatic Brain Injury and Therapeutic Insights.Nuthalapati P, Holmes SE, Altalib HH, Fesharaki-Zadeh A. Int J Mol Sci. 2025 Oct 1; 2025 Oct 1. PMID: 41096867.
• Comment on Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.Canuso CM, Bossie C, Fu DJ, Lane R, Doherty T, Lignugaris A, Fagiolini A, Llorca PM, McIntyre RS, Reif A, Sanacora G, Shelton RC, Vieta E, Young AH, Drevets WC. Am J Psychiatry. 2025 Oct 1. PMID: 41030001.
• Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First Approval.Sanacora G, Ahmed M, Brown B, Cabrera P, Doherty T, Himedan M, Kern DM, Lim L, Lopena O, Naranjo RR Jr, Nuamah I, Sarayani A, Turkoz I, Bowrey HE. Am J Psychiatry. 2025 Oct 1; 2025 Sep 10. PMID: 40926574.
• Ketamine for Depression, but at What Cost? A Review of Ketamine's Neurotoxic Effects From Preclinical and Human Studies.Li SW, Kumpf KT, Urrutia J, Krystal JH, Sanacora G, Wilkinson ST. Am J Psychiatry. 2025 Oct 1; 2025 Sep 10. PMID: 40926573.
• Questionable Data and Design in Esketamine Study.Wilkinson ST, Rhee TG. JAMA Psychiatry. 2025 Oct 1. PMID: 40833767.
• Genetics of Response to ECT, TMS, Ketamine and Esketamine.Franklin CE, Altinay M, Bailey K, Bhati MT, Carr BR, Conroy SK, Khurshid K, McDonald WM, Mickey BJ, Murrough JW, Nestor SM, Nickl-Jockschat T, Reti IM, Sanacora G, Trapp NT, Viswanath B, Wright JH, Zandi PP, Potash JB. Am J Med Genet B Neuropsychiatr Genet. 2025 Oct; 2025 Jun 17. PMID: 40525674.
• Ketamine and Esketamine: Is There a Meaningful Clinical Difference?Wilkinson ST, Rhee TG. J Clin Psychiatry. 2025 Sep 22; 2025 Sep 22. PMID: 41004166.
• Lamotrigine is not associated with differential clinical outcomes in a real-world sample of patients with unipolar depression receiving ketamine or esketamine.Santucci MC, Katz RB, Pittman B, Nikayin S, Wilkinson ST. Psychopharmacology (Berl). 2025 Sep 20; 2025 Sep 20. PMID: 40973876.
• Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial.Kumpf KT, Wilkinson ST, Hu B, Chen R, Krishnan K, Chakrabarti S, Rhee TG, Grezmak T, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Collins KA, Barnett BS, Anand A. J Clin Psychiatry. 2025 Sep 3; 2025 Sep 3. PMID: 40900112.
• Impact of cannabis use on health outcomes and prescription benzodiazepine use.Singh N, Dai Y, Wilkinson ST, Rhee TG, Radhakrishnan R. medRxiv. 2025 Aug 26; 2025 Aug 26. PMID: 40909837.
• A Digital Therapeutic Intervention for Inpatients With Elevated Suicide Risk: A Randomized Clinical Trial.Bryan CJ, Simon P, Wilkinson ST, Allen MH, Perez J, Adler C, Moon K, Astorino L, Carpenter KM, Misquitta L, Brownlowe K, Khazem LR, Hay J, Starkey AG, Tartaglia J, Winston H, Simpson S, Dager AD, Feuerstein S. JAMA Netw Open. 2025 Aug 1; 2025 Aug 1. PMID: 40779267.
• A Transdiagnostic fMRI Dataset With 300+ Deeply Phenotyped Subjects Across Resting and Task States.Samardzija A, Shen X, Greene AS, Mehta S, Iannone S, Simon AJ, Parra F, Luo W, Arora J, Tokoglu F, Hahn CA, Woods SW, Sanacora G, Katz R, Srihari V, Spann MN, Scheinost D, Constable RT. medRxiv. 2025 Jul 16; 2025 Jul 16. PMID: 40791726.
• Does BMI matter when treating depression with esketamine? A retrospective analysis of real-world data.Ansari M, Rhee TG, Santucci MC, Nikayin S. J Affect Disord. 2025 Jul 15; 2025 Apr 2. PMID: 40185405.
• Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study.Zaki N, Chen LN, Lane R, Doherty T, Drevets WC, Morrison RL, Sanacora G, Wilkinson ST, Young AH, Lacerda ALT, Paik JW, Popova V, Fu DJ. Int J Neuropsychopharmacol. 2025 Jun 6. PMID: 40319349.
• Issues in Clinical Trial Design-Lessons From the FDA's Rejection of MDMA.Wilkinson ST, Sanacora G. JAMA Psychiatry. 2025 Jun 1. PMID: 40238126.
• Developing algorithmic psychiatry via multi-level spanning computational models.Halassa MM, Frank MJ, Garety P, Ongur D, Airan RD, Sanacora G, Dzirasa K, Suresh S, Fitzpatrick SM, Rothman DL. Cell Rep Med. 2025 May 20; 2025 Apr 28. PMID: 40300598.
• Patient preference effects in a randomized comparative effectiveness study of electroconvulsive therapy and ketamine for treatment resistant depression: An ELEKT-D trial secondary analysis.Sanacora G, Barnett BS, Hu B, Goes FS, Mathew SJ, Murrough JW, Reti I, Wilkinson ST, Anand A. Psychiatry Res. 2025 May; 2025 Feb 23. PMID: 40049091.
• Ketamine Versus Electroconvulsive Therapy for the Treatment of Depression: A Guide for Clinicians.Elliott SI, B Katz R, B Ostroff R, Ansari M, Holmes SE, Sanacora G. Focus (Am Psychiatr Publ). 2025 Apr; 2025 Apr 15. PMID: 40235610.
• Making Progress in Clinical Trials for Suicide Prevention: A Review.Wilkinson ST, Bryan CJ, Alphs LD, Canuso CM, Ostacher MJ, Price RB, Bloch MH, Zarate CA, Rhee TG. JAMA Psychiatry. 2025 Apr 1. PMID: 39937491.
• Strengthening Safeguards for Psychiatric Uses of Ketamine.Barnett BS, Weiss RD, Sanacora G. JAMA Psychiatry. 2025 Apr 1. PMID: 39937465.
• The genetics of severe depression.Franklin CE, Achtyes E, Altinay M, Bailey K, Bhati MT, Carr BR, Conroy SK, Husain MM, Khurshid KA, Lencz T, McDonald WM, Mickey BJ, Murrough J, Nestor S, Nickl-Jockschat T, Nikayin S, Reeves K, Reti IM, Selek S, Sanacora G, Trapp NT, Viswanath B, Wright JH, Sullivan P, Zandi PP, Potash JB. Mol Psychiatry. 2025 Mar; 2024 Oct 15. PMID: 39406997.
• Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression.Chepke C, Shelton R, Sanacora G, Doherty T, Tsytsik P, Parker N. Int J Neuropsychopharmacol. 2024 Dec 1. PMID: 39611487.
• Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies.Morrison RL, Singh J, Daly E, Fedgchin M, Ochs-Ross R, Karcher K, Lane R, Cooper K, Sanacora G, Maruff P, Drevets WC. Int J Neuropsychopharmacol. 2024 Nov 1. PMID: 39514643.
• Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.Santucci MC, Ansari M, Nikayin S, Radhakrishnan R, Rhee TG, Wilkinson ST. J Clin Psychiatry. 2024 Oct 2; 2024 Oct 2. PMID: 39361411.
• The Role of Awe and Other Psychological Factors in Ketamine's Mechanism of Antidepressant Action.Ansari M, Sanacora G. Biol Psychiatry Glob Open Sci. 2024 Sep; 2024 Sep 16. PMID: 39713125.
• Deficits in prefrontal metabotropic glutamate receptor 5 are associated with functional alterations during emotional processing in bipolar disorder.Asch RH, Worhunsky PD, Davis MT, Holmes SE, Cool R, Boster S, Carson RE, Blumberg HP, Esterlis I. J Affect Disord. 2024 Sep 15; 2024 Jun 13. PMID: 38876317.
• Blood pressure changes during ketamine infusion for the treatment of depression.Ansari M, Pittman B, Tylee DS, Ostroff R, Wilkinson ST, Nikayin S. Gen Hosp Psychiatry. 2024 Sep-Oct; 2024 Jul 4. PMID: 38991311.
• Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial.Jha MK, Wilkinson ST, Krishnan K, Collins KA, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Costi S, Malone D, Nikayin S, Nissen SE, Ostroff R, Reti I, Wolski K, Wang D, Hu B, Mathew SJ, Anand A. JAMA Netw Open. 2024 Jun 3; 2024 Jun 3. PMID: 38916891.
• Depression - Advanced Treatments for Treatment-Resistant Depression.Cristancho M, Fava M, Ingelfinger J, Nikayin S, Sanacora G. N Engl J Med. 2024 May 30. PMID: 38810184.
• Depression - Treatment Options and Managing Depression in Primary Care.Anderson E, Crawford CM, Fava M, Ingelfinger J, Sanacora G, Scott-Vernaglia S, Teel J. N Engl J Med. 2024 May 16. PMID: 38749042.
• Depression - Understanding, Identifying, and Diagnosing.Anderson E, Crawford CM, Fava M, Ingelfinger J, Nikayin S, Sanacora G, Scott-Vernaglia S, Teel J. N Engl J Med. 2024 May 2. PMID: 38692291.
• Author Correction: Synaptic loss and its association with symptom severity in Parkinson's disease.Holmes SE, Honhar P, Tinaz S, Naganawa M, Hilmer AT, Gallezot JD, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis ED, Comley R, Finnema SJ, Carson RE, Matuskey D. NPJ Parkinsons Dis. 2024 Mar 12; 2024 Mar 12. PMID: 38472206.
• The Rapidly Shifting Ketamine Landscape in the US.Wilkinson ST, Palamar JJ, Sanacora G. JAMA Psychiatry. 2024 Mar 1. PMID: 38170542.
• Synaptic loss and its association with symptom severity in Parkinson's disease.Holmes SE, Honhar P, Tinaz S, Naganawa M, Hilmer AT, Gallezot JD, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis ED, Comley R, Finnema SJ, Carson RE, Matuskey D. NPJ Parkinsons Dis. 2024 Feb 24; 2024 Feb 24. PMID: 38402233.
• Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments.Krystal JH, Kaye AP, Jefferson S, Girgenti MJ, Wilkinson ST, Sanacora G, Esterlis I. Proc Natl Acad Sci U S A. 2023 Dec 5; 2023 Nov 27. PMID: 38011560.
• Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol.Kitay BM, Murphy E, Macaluso M, Corlett PR, Hershenberg R, Joormann J, Martinez-Kaigi V, Nikayin S, Rhee TG, Sanacora G, Shelton RC, Thase ME, Wilkinson ST. Psychiatry Res. 2023 Dec; 2023 Oct 30. PMID: 37935086.
• Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST. Drug Discov Today. 2023 Dec; 2023 Nov 2. PMID: 37925136.
• Prefrontal cortex astroglia modulate anhedonia-like behavior.Codeluppi SA, Xu M, Bansal Y, Lepack AE, Duric V, Chow M, Muir J, Bagot RC, Licznerski P, Wilber SL, Sanacora G, Sibille E, Duman RS, Pittenger C, Banasr M. Mol Psychiatry. 2023 Nov; 2023 Sep 11. PMID: 37696873.
• Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS study.Darrow SM, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J Jr, Lisanby SH, Iosifescu D, Murrough JW, Yang H, Weiner RD, Sanacora G, Keefe RSE, Song A, Goodman W, Whitton AE, Potter WZ, Krystal AD. J Affect Disord. 2023 Oct 15; 2023 Jul 17. PMID: 37467805.
• Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions.McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, Gorwood P, Ho R, Kasper S, Kennedy SH, Ly-Uson J, Mansur RB, McAllister-Williams RH, Murrough JW, Nemeroff CB, Nierenberg AA, Rosenblat JD, Sanacora G, Schatzberg AF, Shelton R, Stahl SM, Trivedi MH, Vieta E, Vinberg M, Williams N, Young AH, Maj M. World Psychiatry. 2023 Oct. PMID: 37713549.
• Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, Kakar R, Hassman M, Trivedi RP, Robison R, Gukasyan N, Nayak SM, Hu X, O'Donnell KC, Kelmendi B, Sloshower J, Penn AD, Bradley E, Kelly DF, Mletzko T, Nicholas CR, Hutson PR, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis MC, Nelson-Douthit C, Wilson S, Brown C, Linton W, Ross S, Griffiths RR. JAMA. 2023 Sep 5. PMID: 37651119.
• The Intricate Interaction Between Expectations and Therapeutic Outcomes of Psychedelic Agents.Colloca L, Nikayin S, Sanacora G. JAMA Psychiatry. 2023 Sep 1. PMID: 37405764.
• Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.Castro M, Wilkinson ST, Al Jurdi RK, Petrillo MP, Zaki N, Borentain S, Fu DJ, Turkoz I, Sun L, Brown B, Cabrera P. CNS Drugs. 2023 Aug; 2023 Aug 9. PMID: 37558912.
• Treatment response to esketamine nasal spray in patients with major depressive disorder and acute suicidal ideation or behavior without evidence of early response: a pooled post hoc analysis of ASPIRE.Turkoz I, Lopena O, Salvadore G, Sanacora G, Shelton R, Fu DJ. CNS Spectr. 2023 Aug; 2022 Jul 29. PMID: 35904046.
• Trends in Illicit Ketamine Seizures in the US From 2017 to 2022.Palamar JJ, Wilkinson ST, Carr TH, Rutherford C, Cottler LB. JAMA Psychiatry. 2023 Jul 1. PMID: 37223891.
• Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study.Zaki N, Chen LN, Lane R, Doherty T, Drevets WC, Morrison RL, Sanacora G, Wilkinson ST, Popova V, Fu DJ. Neuropsychopharmacology. 2023 Jul; 2023 May 12. PMID: 37173512.
• Prefrontal Cortex Astroglia Modulate Anhedonia-like Behavior.Codeluppi SA, Xu M, Bansal Y, Lepack AE, Duric V, Chow M, Muir J, Bagot RC, Licznerski P, Wilber SL, Sanacora G, Sibille E, Duman RS, Pittenger C, Banasr M. Res Sq. 2023 Jun 30; 2023 Jun 30. PMID: 37461693.
• Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Altinay M, Aloysi AS, Asghar-Ali AA, Barnett BS, Chang LC, Collins KA, Costi S, Iqbal S, Jha MK, Krishnan K, Malone DA, Nikayin S, Nissen SE, Ostroff RB, Reti IM, Wilkinson ST, Wolski K, Hu B. N Engl J Med. 2023 Jun 22; 2023 May 24. PMID: 37224232.
• Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder.Holmes SE, Asch RH, Davis MT, DellaGioia N, Pashankar N, Gallezot JD, Nabulsi N, Matuskey D, Sanacora G, Carson RE, Blumberg HP, Esterlis I. Biol Psychiatry. 2023 Jun 15; 2022 Nov 8. PMID: 36764853.
• Candidate biomarkers in psychiatric disorders: state of the field.Abi-Dargham A, Moeller SJ, Ali F, DeLorenzo C, Domschke K, Horga G, Jutla A, Kotov R, Paulus MP, Rubio JM, Sanacora G, Veenstra-VanderWeele J, Krystal JH. World Psychiatry. 2023 Jun. PMID: 37159365.
• The Role of Psychotherapy in the Management of Treatment-Resistant Depression.Rogan T, Wilkinson ST. Psychiatr Clin North Am. 2023 Jun; 2023 Mar 15. PMID: 37149349.
• Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study.Leal GC, Souza-Marques B, Mello RP, Bandeira ID, Caliman-Fontes AT, Carneiro BA, Faria-Guimarães D, Guerreiro-Costa LNF, Jesus-Nunes AP, Silva SS, Lins-Silva DH, Fontes MA, Alves-Pereira R, Cordeiro V, Rugieri-Pacheco S, Santos-Lima C, Correia-Melo FS, Vieira F, Sanacora G, Lacerda ALT, Quarantini LC. J Affect Disord. 2023 Jun 1; 2023 Mar 4. PMID: 36871913.
• Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray.Turkoz I, Nelson JC, Wilkinson ST, Borentain S, Macaluso M, Trivedi MH, Williamson D, Sheehan JJ, Salvadore G, Singh J, Daly E. Psychiatry Res. 2023 May; 2023 Mar 16. PMID: 37019044.
• Pharmacological and Somatic Treatment Effects on Suicide in Adults: A Systematic Review and Meta-Analysis.Wilkinson ST, Trujillo Diaz D, Rupp ZW, Kidambi A, Ramirez KL, Flores JM, Avila-Quintero VJ, Rhee TG, Olfson M, Bloch MH. Focus (Am Psychiatr Publ). 2023 Apr; 2023 Apr 14. PMID: 37201149.
• Linking resting-state network fluctuations with systems of coherent synaptic density: A multimodal fMRI and (11)C-UCB-J PET study.Fang XT, Volpi T, Holmes SE, Esterlis I, Carson RE, Worhunsky PD. Front Hum Neurosci. 2023; 2023 Feb 23. PMID: 36908710.
• Prophylactic Efficacy of Riluzole against Anxiety- and Depressive-Like Behaviors in Two Rodent Stress Models.Bansal Y, Fee C, Misquitta KA, Codeluppi SA, Sibille E, Berman RM, Coric V, Sanacora G, Banasr M. Complex Psychiatry. 2023 Jan-Dec; 2023 Feb 3. PMID: 37101541.
• Effects of Electroconvulsive Therapy on Functional Outcomes Among Medicare Patients With Comorbid Depression and Dementia: A Nationwide 1-Year Follow-Up Study.Wilkinson ST, Sint K, Forester BP, Rhee TG. J Clin Psychiatry. 2023 Jan 25; 2023 Jan 25. PMID: 36700843.
• Imaging synaptic density in depression.Holmes SE, Abdallah C, Esterlis I. Neuropsychopharmacology. 2023 Jan; 2022 Jun 29. PMID: 35768568.
• Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis.Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, Krystal JH, Sanacora G, Wilkinson ST. JAMA Psychiatry. 2022 Dec 1. PMID: 36260324.
• International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators.Price RB, Kissel N, Baumeister A, Rohac R, Woody ML, Ballard ED, Zarate CA Jr, Deakin W, Abdallah CG, Feder A, Charney DS, Grunebaum MF, Mann JJ, Mathew SJ, Gallagher B, McLoughlin DM, Murrough JW, Muthukumaraswamy S, McMillan R, Sumner R, Papakostas G, Fava M, Hock R, Phillips JL, Blier P, Shiroma P, Šóš P, Su TP, Chen MH, Tiger M, Lundberg J, Wilkinson ST, Wallace ML. Mol Psychiatry. 2022 Dec; 2022 Sep 7. PMID: 36071111.
• At-home ketamine; still a lot to learn.Wilkinson ST, Sanacora G. J Affect Disord. 2022 Dec 1; 2022 Sep 5. PMID: 36067887.
• Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.Feeney A, Hoeppner BB, Freeman MP, Flynn M, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, DeBattista C, Ionescu DF, Cusin C, Papakostas GI, Jha MK, Fava M. J Clin Psychiatry. 2022 Nov 14; 2022 Nov 14. PMID: 36383742.
• A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine.Bloomfield-Clagett B, Ballard ED, Greenstein DK, Wilkinson ST, Grunebaum MF, Murrough JW, Mathew SJ, Phillips JL, Fava M, Sanacora G, Zarate CA. Int J Neuropsychopharmacol. 2022 Oct 25. PMID: 35994774.
• Ketamine in the Real World: Where Do We Go From Here?Wilkinson ST. J Clin Psychiatry. 2022 Sep 14; 2022 Sep 14. PMID: 36112579.
• Brain-phenotype models fail for individuals who defy sample stereotypes.Greene AS, Shen X, Noble S, Horien C, Hahn CA, Arora J, Tokoglu F, Spann MN, Carrión CI, Barron DS, Sanacora G, Srihari VH, Woods SW, Scheinost D, Constable RT. Nature. 2022 Sep; 2022 Aug 24. PMID: 36002572.
• Catatonia After COVID-19: A Case Series.Nikayin S, Chaffkin J, Ostroff RB. J ECT. 2022 Sep 1; 2022 Mar 1. PMID: 35220361.
• Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting.Nikayin S, Rhee TG, Cunningham ME, de Fontnouvelle CA, Ostroff RB, Sanacora G, Wilkinson ST. JAMA Psychiatry. 2022 Jul 1. PMID: 35544190.
• Long-term safety of ketamine and esketamine in treatment of depression.Nikayin S, Murphy E, Krystal JH, Wilkinson ST. Expert Opin Drug Saf. 2022 Jun; 2022 Apr 19. PMID: 35416105.
• A Novel Biomarker of Neuronal Glutamate Metabolism in Nonhuman Primates Using Localized (1)H-Magnetic Resonance Spectroscopy: Development and Effects of BNC375, an α7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator.Miller CO, Gantert LT, Previs SF, Chen Y, Anderson KD, Thomas JM, Sanacora G, Uslaner JM, Rothman DL, Mason GF. Biol Psychiatry Cogn Neurosci Neuroimaging. 2022 Jun; 2020 Sep 29. PMID: 33309567.
• An Update on Community Ketamine Practices.O'Brien B, Wilkinson ST, Mathew SJ. Am J Psychiatry. 2022 May. PMID: 35491568.
• A Choice-Based Conjoint Analysis of the Psychiatrist Decision-Making Process Used in Determining When to Discharge Adults With Major Depressive Disorder Hospitalized for Active Suicidal Ideation With Intent.Voelker J, Wilkinson ST, Katz EG, Nash AI, Daly E, Ali A, Lovink A, Stahl J, Desai A, Kuvadia H, Neslusan C, Sheehan JJ. J Nerv Ment Dis. 2022 May 1. PMID: 34937847.
• Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study.Ochs-Ross R, Wajs E, Daly EJ, Zhang Y, Lane R, Lim P, Drevets WC, Steffens DC, Sanacora G, Jamieson C, Hough D, Manji H, Singh JB. Am J Geriatr Psychiatry. 2022 May; 2021 Oct 6. PMID: 34750057.
• mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression.Averill LA, Averill CL, Gueorguieva R, Fouda S, Sherif M, Ahn KH, Ranganathan M, D'Souza DC, Southwick SM, Sanacora G, Duman RS, Krystal JH, Abdallah CG. J Affect Disord. 2022 Apr 15; 2022 Jan 29. PMID: 35101523.
• Prefrontal Glutamate Neurotransmission in PTSD: A Novel Approach to Estimate Synaptic Strength in Vivo in Humans.Averill LA, Jiang L, Purohit P, Coppoli A, Averill CL, Roscoe J, Kelmendi B, De Feyter HM, de Graaf RA, Gueorguieva R, Sanacora G, Krystal JH, Rothman DL, Mason GF, Abdallah CG. Chronic Stress (Thousand Oaks). 2022 Jan-Dec; 2022 Apr 11. PMID: 35434443.
• Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Focus (Am Psychiatr Publ). 2022 Apr; 2022 Apr 22. PMID: 37153136.
• Imaging the effect of ketamine on synaptic density (SV2A) in the living brain.Holmes SE, Finnema SJ, Naganawa M, DellaGioia N, Holden D, Fowles K, Davis M, Ropchan J, Emory P, Ye Y, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, Sanacora G, Krystal JH, Carson RE, Esterlis I. Mol Psychiatry. 2022 Apr; 2022 Feb 15. PMID: 35165397.
• Advanced training in interventional psychiatry.Nikayin S, Taylor JJ, Ostroff RB. J Neurol Sci. 2022 Mar 15; 2021 Dec 16. PMID: 34974201.
• Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review.Bandeira ID, Lins-Silva DH, Cavenaghi VB, Dorea-Bandeira I, Faria-Guimarães D, Barouh JL, Jesus-Nunes AP, Beanes G, Souza LS, Leal GC, Sanacora G, Miguel EC, Sampaio AS, Quarantini LC. Harv Rev Psychiatry. 2022 Mar-Apr 01. PMID: 35267254.
• The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders.Sanacora G, Yan Z, Popoli M. Nat Rev Neurosci. 2022 Feb; 2021 Dec 10. PMID: 34893785.
• Pharmacological and somatic treatment effects on suicide in adults: A systematic review and meta-analysis.Wilkinson ST, Trujillo Diaz D, Rupp ZW, Kidambi A, Ramirez KL, Flores JM, Avila-Quintero VJ, Rhee TG, Olfson M, Bloch MH. Depress Anxiety. 2022 Feb; 2021 Nov 11. PMID: 34762330.
• Lower synaptic density is associated with psychiatric and cognitive alterations in obesity.Asch RH, Holmes SE, Jastreboff AM, Potenza MN, Baldassarri SR, Carson RE, Pietrzak RH, Esterlis I. Neuropsychopharmacology. 2022 Jan; 2021 Jul 22. PMID: 34294874.
• Twenty-year trends in use of electroconvulsive therapy among homeless and domiciled veterans with mental illness.Tsai J, Szymkowiak D, Wilkinson ST, Holtzheimer PE. CNS Spectr. 2021 Dec 13; 2021 Dec 13. PMID: 34895380.
• Association of ECT With Risks of All-Cause Mortality and Suicide in Older Medicare Patients.Rhee TG, Sint K, Olfson M, Gerhard T, H Busch S, Wilkinson ST. Am J Psychiatry. 2021 Dec; 2021 Sep 10. PMID: 34503341.
• Utilization of Electroconvulsive Therapy for Older Homeless Adults Covered by Medicare.Wilkinson ST, Rhee TG, Tsai J. Psychiatr Q. 2021 Dec; 2021 Sep 1. PMID: 34468909.
• The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial.Chouairi F, Fuery MA, Mullan CW, Caraballo C, Sen S, Maulion C, Wilkinson ST, Surti T, McCullough M, Miller PE, Pacor J, Leifer ES, Felker GM, Velazquez EJ, Fiuzat M, O'Connor CM, Januzzi JL, Desai NR, Ahmad T. J Card Fail. 2021 Dec; 2021 Jun 22. PMID: 34166799.
• Correction to: Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS).Pizzagalli DA, Smoski M, Ang YS, Whitton AE, Sanacora G, Mathew SJ, Nurnberger J Jr, Lisanby SH, Iosifescu DV, Murrough JW, Yang H, Weiner RD, Calabrese JR, Goodman W, Potter WZ, Krystal AD. Neuropsychopharmacology. 2021 Nov. PMID: 34389811.
• Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk.Nikayin S, Sanacora G. CNS Drugs. 2021 Oct; 2021 Sep 7. PMID: 34491545.
• Mental Health Care Resource Utilization and Barriers to Receiving Mental Health Services Among US Adults With a Major Depressive Episode and Suicidal Ideation or Behavior With Intent.Voelker J, Cai Q, Daly E, Connolly N, Pesa J, Sheehan JJ, Wilkinson ST. J Clin Psychiatry. 2021 Sep 14; 2021 Sep 14. PMID: 34529898.
• Cell-type specific modulation of NMDA receptors triggers antidepressant actions.Pothula S, Kato T, Liu RJ, Wu M, Gerhard D, Shinohara R, Sliby AN, Chowdhury GMI, Behar KL, Sanacora G, Banerjee P, Duman RS. Mol Psychiatry. 2021 Sep; 2020 Jun 2. PMID: 32488125.
• Identifying brain networks in synaptic density PET ((11)C-UCB-J) with independent component analysis.Fang XT, Toyonaga T, Hillmer AT, Matuskey D, Holmes SE, Radhakrishnan R, Mecca AP, van Dyck CH, D'Souza DC, Esterlis I, Worhunsky PD, Carson RE. Neuroimage. 2021 Aug 15; 2021 May 15. PMID: 34000404.
• The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study.Feeney A, Hock RS, Freeman MP, Flynn M, Hoeppner B, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Fava M, Papakostas GI. Eur Neuropsychopharmacol. 2021 Aug; 2021 Jun 3. PMID: 34090255.